Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Publikation

Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

Wissenschaftlicher Artikel/Review - 29.04.2010

Hawle H, Hess Dagmar, Mueller A, Thürlimann Beat

Zitation

Hawle H, Hess D, Mueller A, Thürlimann B. Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer. Case Rep Oncol 2010; 3:131-136.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Case Rep Oncol 2010; 3

Veröffentlichungsdatum

29.04.2010

eISSN (Online)

1662-6575

Seiten

131-136

Kurzbeschreibung/Zielsetzung

We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission was temporarily lost after fulvestrant was tentatively withdrawn (63 months after treatment start), but was re-achieved after renewal of half-dose treatment and last reconfirmed 90 months after treatment start. The pharmacokinetic profile provides evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might explain both: toxicity and extraordinary efficacy.